Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 and ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Adults who developed severe obesity before the age of 18 are nearly three times more likely than those who developed the ...

Plainsboro, New Jersey Monday, May 5, 2025, 14:00 Hrs [IST] ...

Currently, more than 42% of adults in the United States have obesity. Among young people, about 1 in 5 adolescents are also ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Higher BMI cutoffs are needed to diagnose overweight and obesity in male athletes, researchers reported in a study published ...

Obesity and poor diet quality are major issues among adults with severe mental illness, and current weight management ...

A decision is expected in the fourth quarter of 2025.

The wildly popular obesity drugs – Wegovy developed by Novo Nordisk and Zepbound by Eli Lilly – are known as GLP-1 receptor ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.